Vulvar Neoplasms
14
4
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
14%
2 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Danish Vulva Cancer Recurrence Study
Agnostic Therapy in Rare Solid Tumors
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Quality of Life in Patients Undergone Vulvar Reconstruction After Vulvar Cancer Resection (3233)
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
Impact of the COVID-19 Pandemic in Gynecological Oncology
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage
Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology
Magnetic Resonance Imaging Guided Gynecologic Brachytherapy
Questionnaire Study for Gynecological Cancer Survivors